

**PROPOSED PLACEMENT TO RAISE GROSS PROCEEDS OF NO LESS THAN S\$6,000,000
– RESULTS OF PROPOSED PLACEMENT**

1. INTRODUCTION

- 1.1. The Board of Directors of iX Biopharma Ltd. (the “**Company**” and together with its subsidiaries, the “**Group**”) (the “**Board**” or the “**Directors**”) refers to its announcement dated 12 February 2026 in relation to the entry into a placement agreement with Oversea-Chinese Banking Corporation Limited (“**Launch Announcement**”).
- 1.2. Unless otherwise defined, all capitalised terms used herein shall have the same meaning as ascribed to them in the Launch Announcement.
- 1.3. Further to the Launch Announcement, the Company wishes to announce that the Placement Agent, in consultation with the Company, has closed the book of orders for the Proposed Placement on 13 February 2026.
- 1.4. The Board is also pleased to announce that, in view of the strong investor demand, the Company and the Placement Agent have agreed to upsize the Proposed Placement by increasing the number of New Shares to be issued and raising additional gross proceeds of approximately S\$9,008,400. Consequently, a total of 75,800,000 New Shares will be issued at the Placement Price, thus increasing the aggregate gross proceeds raised to S\$15,008,400, an approximately 150% increase over the minimum gross proceeds of S\$6,000,000 as previously announced in the Launch Announcement.
- 1.5. On 13 February 2026, the Company allotted and issued 1,049,650 new Shares pursuant to the exercise of existing warrants, increasing the issued and paid-up share capital of the Company to 960,493,895 Shares (“**Existing Share Capital**”). The 75,800,000 New Shares represent approximately 7.89% of the Existing Share Capital as at the date of this announcement and will represent approximately 7.31% of the enlarged issued and paid-up share capital of the Company of 1,036,293,895 Shares (assuming no changes to the number of Shares up to Completion). The Company does not have any treasury shares or subsidiary holdings.

2. USE OF PROCEEDS

- 2.1. Further to the Launch Announcement and in view of the additional gross proceeds raised, the Company wishes to update shareholders that it intends to apply the gross proceeds from the Proposed Placement in the following estimated proportions:

Proposed use of gross proceeds	S\$	% of gross proceeds
(a) Funding interim requirement in connection with the U.S. Government Contract and other general working capital and fees and expenses incurred in connection with the Proposed Placement of approximately S\$620,000	13,008,400	86.67
(b) Repayment of debts	2,000,000	13.33
Total	S\$15,008,400	100.00%

- 2.2. Pending the deployment of the Net Proceeds (being the gross proceeds after deduction of fees and expenses incurred in connection with the Proposed Placement of approximately S\$620,000), such Net Proceeds may be deposited with banks or financial institutions, invested in short-term money market instruments or marketable securities, and/or used for any other purpose on a short-term basis, as the Company may, in its absolute discretion, deem fit from time to time.
- 2.3. The Company will make periodic announcement(s) as to the use of the Net Proceeds as and when such proceeds are materially disbursed and whether such use is in accordance with the stated use. The Company will also provide a status report on the use of the Net Proceeds in the Company's interim and full-year financial statements issued under Rule 705 of the Catalist Rules and the Company's annual reports. Where the Net Proceeds have been used for working capital purposes, the Company will provide a breakdown with specific details on how the Net Proceeds have been applied in the announcements and status reports. Where there is any material deviation from the stated use of the Net Proceeds, the Company will announce the reasons for such deviation.

3. MANDATE FOR THE ISSUANCE OF THE NEW SHARES

- 3.1. As set out in the Launch Announcement, the New Shares will be allotted and issued pursuant to the General Mandate granted by the shareholders of the Company at the 2025 AGM. Pursuant to the General Mandate, the Company may issue up to 446,746,947 Shares other than on a *pro rata* basis.
- 3.2. As at the date of this announcement, the Company has issued 67,000,000 new ordinary shares under the General Mandate. Accordingly, the 75,800,000 New Shares to be issued pursuant to the Proposed Placement falls within the limits of the General Mandate.

4. ADDITIONAL LISTING APPLICATION

The Company will be applying to the SGX-ST, through its sponsor, UOB Kay Hian Private Limited, for the dealing in, listing of and quotation for the New Shares on the Catalist and will make the necessary announcement(s) upon receipt of the listing and quotation notice from SGX-ST.

5. INTERESTS OF DIRECTORS AND SUBSTANTIAL SHAREHOLDERS

None of the Directors or substantial shareholders of the Company or any of their respective associates has any interest, direct or indirect, in the Proposed Placement, other than through their respective shareholding interests in the Company (if any).

6. RESPONSIBILITY STATEMENT

The Directors collectively and individually accept full responsibility for the accuracy of the information given in this announcement and confirm after making all reasonable enquiries, that to the best of their knowledge and belief, this announcement constitutes full and true disclosure of all material facts about the Proposed Placement, the Company and its subsidiaries in relation to the Proposed Placement, and the Directors are not aware of any facts the omission of which would make any statement in this announcement misleading. Where information in this announcement has been extracted from published or otherwise publicly available sources or obtained from a named source, the sole responsibility of the Directors has been to ensure that such information has been accurately and correctly extracted from those sources and/or reproduced in this announcement in its proper form and context.

7. FURTHER ANNOUNCEMENTS

The Company will continue to keep its shareholders updated and release announcements relating to the Proposed Placement (including any material developments and progress made) as may be appropriate from time to time.

8. CAUTIONARY STATEMENT

Shareholders and potential investors should note that the Proposed Placement is subject to the fulfilment of, *inter alia*, the conditions set out under the Placement Agreement, and accordingly, should exercise caution when trading in the Shares of the Company. Persons who are in doubt as to the action they should take should consult their legal, financial, tax or other professional advisers.

By Order of the Board
IX BIOPHARMA LTD.

Eddy Lee Yip Hang
Chairman & CEO

13 February 2026

This announcement has been reviewed by the Company's sponsor, UOB Kay Hian Private Limited (the "Sponsor").

This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "SGX-ST") and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr. Lance Tan, Senior Vice President, at 83 Clemenceau Avenue, #10-01 UE Square, Singapore 239920, telephone: (65) 6590 6881.

IMPORTANT NOTICE

THE NEW SHARES HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED, (THE "**SECURITIES ACT**") OR THE SECURITIES LAWS OF ANY STATE OF THE U.S. OR OTHER JURISDICTION, AND THE NEW SHARES MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES, EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND APPLICABLE STATE OR LOCAL SECURITIES LAWS.